LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity
TLDR
LysSAP26 is a new endolysin that can be applied to treat MDR A. baumannii, E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli infections, targeting both Gram-positive and Gram-negative bacteria.Abstract:
Multidrug-resistant (MDR) bacteria are a major threat to public health. Bacteriophage endolysins (lysins) are a promising alternative treatment to traditional antibiotics. However, the lysins currently under development are still underestimated. Herein, we cloned the lysin from the SAP-26 bacteriophage genome. The recombinant LysSAP26 protein inhibited the growth of carbapenem-resistant Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, oxacillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium with minimum inhibitory concentrations of 5~80 µg/mL. In animal experiments, mice infected with A. baumannii were protected by LysSAP26, with a 40% survival rate. Transmission electron microscopy analysis confirmed that LysSAP26 treatment resulted in the destruction of bacterial cell walls. LysSAP26 is a new endolysin that can be applied to treat MDR A. baumannii, E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli infections, targeting both Gram-positive and Gram-negative bacteria.read more
Citations
More filters
Journal ArticleDOI
Endolysin, a Promising Solution against Antimicrobial Resistance.
Mujeeb ur Rahman,Weixiao Wang,Qingqing Sun,Junaid Ali Shah,Chao Li,Yanmei Sun,Yuanrui Li,Bailing Zhang,Wei Chen,Shiwei Wang +9 more
TL;DR: This review comprehensively introduces the structures and activities of endolysins and summarize the latest application progress of recombinant endolySins in the fields of medical treatment, pathogen diagnosis, food safety, and agriculture.
Journal ArticleDOI
Bacteriophage-encoded enzymes destroying bacterial cell membranes and walls, and their potential use as antimicrobial agents.
Łukasz Grabowski,Krzysztof Łepek,Małgorzata Stasiłojć,Katarzyna Kosznik-Kwaśnicka,Karolina Zdrojewska,Monika Maciąg-Dorszyńska,Grzegorz Węgrzyn,Alicja Węgrzyn +7 more
TL;DR: In this article, the authors present and discuss the current knowledge on the processes of bacteriophage-mediated bacterial cell lysis, with special emphasis on enzymes involved in them, and possibilities of the practical use of these enzymes as antibacterial agents are underlined and perspectives of this aspect will be presented.
Journal ArticleDOI
A Novel Acinetobacter baumannii Bacteriophage Endolysin LysAB54 With High Antibacterial Activity Against Multiple Gram-Negative Microbes
Fazal Mehmood Khan,Vijay Singh Gondil,Changchang Li,Mengwei Jiang,Junhua Li,Junping Yu,Hongping Wei,Hang Yang +7 more
TL;DR: In this paper, an A. baumannii bacteriophage p54 was isolated and characterized, and a novel endolysin, namely LysAB54, showing low similarity with other well-known related endolysins, was cloned, expressed, and characterized from the bacteria p54.
Journal ArticleDOI
Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges.
Firzan Nainu,Andi Dian Permana,Nana Juniarti Natsir Djide,Qonita Kurnia Anjani,Qonita Kurnia Anjani,Rifka Nurul Utami,Rifka Nurul Utami,Nur Rahma Rumata,Jianye Zhang,Talha Bin Emran,Jesus Simal-Gandara +10 more
TL;DR: In this paper, the authors discuss the emergence of AMR and argue for the importance of addressing this issue by discovering novel synthetic or naturally occurring antibacterial compounds and providing insights into the application of various drug delivery approaches, delivered through numerous routes, in comparison with conventional delivery systems.
Journal ArticleDOI
Novel antimicrobial agents for combating antibiotic-resistant bacteria.
TL;DR: In this article , a review of the promising antimicrobial therapies for the treatment of multidrug-resistant bacterial infections is presented, focusing on preclinical and clinical investigations, as well as combinatorial approaches.
References
More filters
Journal ArticleDOI
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli,Elena Carrara,Alessia Savoldi,Stéphan Juergen Harbarth,Marc Mendelson,Dominique L Monnet,Céline Pulcini,Gunnar Kahlmeter,Jan Kluytmans,Yehuda Carmeli,Marc Ouellette,Kevin Outterson,Jean B. Patel,Marco Cavaleri,Edward Cox,Christopher R. Houchens,M Lindsay Grayson,Paul Hansen,Nalini Singh,Ursula Theuretzbacher,Nicola Magrini,Aaron O. Aboderin,Seif Al-Abri,Nordiah Awang Jalil,Nur Benzonana,Sanjay Bhattacharya,Adrian Brink,Francesco Robert Burkert,Otto Cars,Giuseppe Cornaglia,Oliver J. Dyar,Alexander W. Friedrich,Ana Cristina Gales,Sumanth Gandra,Christian G. Giske,Debra A. Goff,Herman Goossens,Thomas Gottlieb,Manuel Guzman Blanco,Waleria Hryniewicz,Deepthi Kattula,Timothy Jinks,Souha S. Kanj,Lawrence Kerr,Marie-Paule Kieny,Yang Soo Kim,Roman S. Kozlov,Jaime Labarca,Ramanan Laxminarayan,Karin Leder,Leonard Leibovici,Gabriel Levy-Hara,Jasper Littman,Surbhi Malhotra-Kumar,Vikas Manchanda,Lorenzo Moja,Babacar Ndoye,Angelo Pan,David L. Paterson,Mical Paul,Haibo Qiu,Pilar Ramon-Pardo,Jesús Rodríguez-Baño,Maurizio Sanguinetti,Sharmila Sengupta,Mike Sharland,Massinissa Si-Mehand,Lynn L. Silver,Wonkeung Song,Martin Steinbakk,Jens Thomsen,Guy E. Thwaites,Jos W. M. van der Meer,Nguyen Van Kinh,Silvio Vega,Maria Virginia Villegas,Agnes Wechsler-Fördös,Heiman F. L. Wertheim,Evelyn Wesangula,Neil Woodford,Fidan O Yilmaz,Anna Zorzet +81 more
TL;DR: Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria, and include antibiotic-resistant bacteria responsible for community-acquired infections.
Journal ArticleDOI
Development of a Multilocus Sequence Typing Scheme for Characterization of Clinical Isolates of Acinetobacter baumannii
Sergio G. Bartual,Harald Seifert,Corinna Hippler,M. Angeles Domínguez Luzon,Hilmar Wisplinghoff,Francisco Rodriguez-Valera +5 more
TL;DR: The MLST scheme provides a high level of resolution and an excellent tool for studying the population structure and long-term epidemiology of A. baumannii.
Journal ArticleDOI
Bacteriophage Lysins as Effective Antibacterials
TL;DR: Lysins are highly evolved enzymes produced by bacteriophage to digest the bacterial cell wall for phage progeny release and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable, may be a much needed anti-infective in an age of mounting antibiotic resistance.
Journal ArticleDOI
The Recombinant Phage Lysin LysK Has a Broad Spectrum of Lytic Activity against Clinically Relevant Staphylococci, Including Methicillin-Resistant Staphylococcus aureus
Sarah O'Flaherty,Sarah O'Flaherty,Aidan Coffey,William J. Meaney,Gerald F. Fitzgerald,R.P. Ross +5 more
TL;DR: Lactococcal lysates containing recombinant LysK were found to inhibit a range of different species of staphylococci isolated from bovine and human infection sources, including methicillin-resistant Staphylitis aureus.
Journal ArticleDOI
Cell Wall Hydrolases in Bacteria: Insight on the Diversity of Cell Wall Amidases, Glycosidases and Peptidases Toward Peptidoglycan.
Aurore Vermassen,Sabine Leroy,Régine Talon,Christian Provot,Magdalena Popowska,Mickaël Desvaux +5 more
TL;DR: It is stressed that the CWHs frequently display a modular architecture combining multiple and/or different catalytic domains, including some lytic transglycosylases as well as CW binding domains, in bacterial cells.